Georgia Salanti, PhD; Fotini K. Kavvoura, MD; John P.A. Ioannidis, MD
Grant Support: Dr. Kavvoura was funded by a PENED grant, co-financed by the European Union and the Greek Ministry of Development-General Secretariat of Research and Technology.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: John P.A. Ioannidis, MD, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece; e-mail, email@example.com.
Current Author Addresses: Drs. Salanti, Kavvoura, and Ioannidis: Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
Several treatment options exist for many conditions. Randomized trial evidence on the relative merits of various options may be missing or biased.
To examine the patterns of trial evidence (network geometry) and explain their implications for the interpretation of the existing evidence on a treatment's relative effectiveness.
PubMed and Thompson ISI Web of Knowledge (last search April 2007).
Published networks of randomized trials that included at least 4 treatments were identified.
For each network, data on the number of studies per treatment comparison were extracted by one investigator and verified by a second investigator.
Indices were adopted from the ecological literature that measure diversity (number of treatments and how often they were tested) and co-occurrence (whether some treatment comparisons were preferred and others avoided). Eighteen eligible treatment networks were identified for different diseases, involving 4 to 16 alternative treatments and 10 to 84 trials. Networks in which 1 option (placebo or no treatment) was the typical comparator were star-shaped, even though several treatments might have had proven effectiveness. Other networks had different shapes. Some showed important co-occurrence that avoided specific head-to-head comparisons. Comparison choices sometimes seemed justified, such as when newer treatments were not compared with older ones already shown to be inferior, whereas other choices seemed to reflect preference bias.
Networks evolve over time as new trials accumulate, and their geometry may change. Statistical testing for co-occurrence is underpowered when few trials exist.
Evaluation of the geometry of a treatment network can offer valuable insights for the interpretation of total evidence when many treatment options are available.
Salanti G, Kavvoura FK, Ioannidis JP. Exploring the Geometry of Treatment Networks. Ann Intern Med. 2008;148:544–553. doi: 10.7326/0003-4819-148-7-200804010-00011
Download citation file:
Published: Ann Intern Med. 2008;148(7):544-553.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Hematology/Oncology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use